Toll Free: 1-888-928-9744

Insulin Resistance - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Insulin Resistance - Pipeline Review, H1 2016

Global Markets Direct's, 'Insulin Resistance - Pipeline Review, H1 2016', provides an overview of the Insulin Resistance pipeline landscape. The report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Insulin Resistance - The report reviews pipeline therapeutics for Insulin Resistance by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Insulin Resistance therapeutics and enlists all their major and minor projects - The report assesses Insulin Resistance therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Insulin Resistance Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Insulin Resistance - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Insulin Resistance Overview 7 Therapeutics Development 8 Pipeline Products for Insulin Resistance - Overview 8 Pipeline Products for Insulin Resistance - Comparative Analysis 9 Insulin Resistance - Therapeutics under Development by Companies 10 Insulin Resistance - Therapeutics under Investigation by Universities/Institutes 11 Insulin Resistance - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Insulin Resistance - Products under Development by Companies 14 Insulin Resistance - Products under Investigation by Universities/Institutes 15 Insulin Resistance - Companies Involved in Therapeutics Development 16 AUS Bio Limited 16 Genentech, Inc. 17 Genfit SA 18 GlaxoSmithKline Plc 19 Hadasit Medical Research Services & Development Ltd 20 Mertiva AB 21 Prometheon Pharma, LLC 22 Sanofi 23 Insulin Resistance - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 BFKB-8488A - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 elafibranor - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 englerin A - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 FC-98 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 MD-960 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Peptide for Obesity and Insulin Resistance - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 SAR-088 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecule for Hypertension and Insulin Resistance - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SYM-401 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Synthetic Peptide to Inhibit Protein Kinase C for Type-2 diabetes and Insulin Resistance - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Insulin Resistance - Recent Pipeline Updates 52 Insulin Resistance - Dormant Projects 58 Insulin Resistance - Product Development Milestones 60 Featured News & Press Releases 60 Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 60 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
Number of Products under Development for Insulin Resistance, H1 2016 8 Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Insulin Resistance - Pipeline by AUS Bio Limited, H1 2016 16 Insulin Resistance - Pipeline by Genentech, Inc., H1 2016 17 Insulin Resistance - Pipeline by Genfit SA, H1 2016 18 Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H1 2016 19 Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016 20 Insulin Resistance - Pipeline by Mertiva AB, H1 2016 21 Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H1 2016 22 Insulin Resistance - Pipeline by Sanofi, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Insulin Resistance Therapeutics - Recent Pipeline Updates, H1 2016 52 Insulin Resistance - Dormant Projects, H1 2016 58 Insulin Resistance - Dormant Projects (Contd..1), H1 2016 59

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.